MARKETVUE® REPORT: Over 80% of U.S. gastroenterologists have prescribed Dupixent for Eosinophilic Esophagitis since its 2022 approval
First-to-market Regeneron/Sanofi's Dupixent (dupilumab) sees strong uptake in Eosinophilic Esophagitis (EoE) since its May 2022 FDA approval, according to findings from REACH Market Research. NEWTON, Mass., Feb. 21, 2023 /PRNewswire/ -- Despite being recognized [...]
5 Solutions to Overcome Challenges Conducting Rare Disease Epidemiology
Epidemiology and patient population dynamics are at the core of understanding any disease market. For rare diseases, getting a firm grasp of the disease prevalence and incidence, diagnosis rates, treatment rates, representation of clinically [...]
3 Key Insights for Rare Disease Drug Developers: GSD Type 1a
Rare disease market research that captures the voice of the patient is indispensable for understanding a rare disease market. Moreover, because treatment planning for rare diseases is often a process [...]
Hematologists Report A Strong Willingness To Prescribe Novartis’ Adakveo And Global Blood Therapeutics’ Oxbryta But Are Holding Back Due To COVID-19, Treatment Costs, And Patients Being Well-Managed On Current Therapy
A study with 50 U.S. hematologists reveals that approximately one-third have already prescribed Adakveo or Oxbryta Newton, MA., September 30, 2020 — Sickle cell disease (SCD) is a chronic, [...]
MARKETVUE® REPORT: Over 80% of U.S. gastroenterologists have prescribed Dupixent for Eosinophilic Esophagitis since its 2022 approval
First-to-market Regeneron/Sanofi's Dupixent (dupilumab) sees strong uptake in Eosinophilic Esophagitis (EoE) since its May 2022 FDA approval, according to findings from REACH Market Research. NEWTON, Mass., Feb. 21, 2023 /PRNewswire/ -- Despite being recognized [...]
5 Solutions to Overcome Challenges Conducting Rare Disease Epidemiology
Epidemiology and patient population dynamics are at the core of understanding any disease market. For rare diseases, getting a firm grasp of the disease prevalence and incidence, diagnosis rates, treatment rates, representation of clinically [...]
3 Key Insights for Rare Disease Drug Developers: GSD Type 1a
Rare disease market research that captures the voice of the patient is indispensable for understanding a rare disease market. Moreover, because treatment planning for rare diseases is often a process [...]
Hematologists Report A Strong Willingness To Prescribe Novartis’ Adakveo And Global Blood Therapeutics’ Oxbryta But Are Holding Back Due To COVID-19, Treatment Costs, And Patients Being Well-Managed On Current Therapy
A study with 50 U.S. hematologists reveals that approximately one-third have already prescribed Adakveo or Oxbryta Newton, MA., September 30, 2020 — Sickle cell disease (SCD) is a chronic, [...]